(UPDATED FEBRUARY 8) Last month’s granting of an Amgen permanent injunction motion in its cholesterol drug patent dispute with Sanofi and Regeneron would “give another arrow in the quiver” of those seeking permanent injunctions in similar cases, if it is upheld on appeal
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
Tarun Gandhi joins us for our ‘Five minutes with’ series to discuss the biggest misconception about IP, the importance of staying curious, and his biggest inspiration
Latham & Watkins client CoStar filed an opposition brief against Crexi, arguing that their motion to stay is a distraction from an imminent copyright trial